| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Fluorine-18 artanserin can be used to manufacture artanserin[1].
|
|---|---|
| References | |
| Additional Infomation |
Altanserin is a member of quinazolines.
|
| Molecular Formula |
C22H22N3O2FS
|
|---|---|
| Molecular Weight |
411.49238
|
| Exact Mass |
411.142
|
| CAS # |
76330-71-7
|
| Related CAS # |
Altanserin hydrochloride;1135280-78-2
|
| PubChem CID |
3033677
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.37 g/cm3
|
| Boiling Point |
601ºC at 760 mmHg
|
| Flash Point |
317.3ºC
|
| Index of Refraction |
1.674
|
| LogP |
3.731
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
630
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SMYALUSCZJXWHG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
|
| Chemical Name |
3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~19.23 mg/mL (~46.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.92 mg/mL (4.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 19.2 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4302 mL | 12.1510 mL | 24.3019 mL | |
| 5 mM | 0.4860 mL | 2.4302 mL | 4.8604 mL | |
| 10 mM | 0.2430 mL | 1.2151 mL | 2.4302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01398189 | Unknown status | Drug: clozapine | Schizoaffective Disorder Schizophrenia |
Seoul National University Bundang Hospital | 2011-07 | Not Applicable |
| NCT03970239 | Unknown status | Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)- benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) |
Impulse Control Disorders Parkinson Disease |
Hospices Civils de Lyon | 2019-05-13 | Not Applicable |
| NCT01296802 | Completed | Drug: dexfenfluramine | Amphetamine Abuse Amphetamine-Related Disorders |
University of Zurich | 2006-04 | Not Applicable |
| NCT05942716 | Not yet recruiting | Drug: Administration of a PET radiotracer |
Tourette Disorder | Hospices Civils de Lyon | 2023-12-01 | Phase 2 |
| NCT00581282 | Withdrawn | Radiation: PET scan Other: fMRI |
Substance Abuse Disorder | University of California, Irvine | 2005-12 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
